| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(20)30449-6 |
| P698 | PubMed publication ID | 32926841 |
| P50 | author | Johann de Bono | Q43249916 |
| Cora Sternberg | Q50385202 | ||
| Roberto Iacovelli | Q57047350 | ||
| P2093 | author name string | Karim Fizazi | |
| Elizabeth M Poole | |||
| Stéphane Oudard | |||
| Daniel Castellano | |||
| Ronald de Wit | |||
| Bertrand Tombal | |||
| Bohuslav Melichar | |||
| Gaetano Facchini | |||
| Carole Helissey | |||
| Susan Feyerabend | |||
| Christian Wülfing | |||
| Gero Kramer | |||
| Christine Theodore | |||
| Jean-Christophe Eymard | |||
| Joan Carles | |||
| Michael Liontos | |||
| Samira Bensfia | |||
| Ásgerður Sverrisdóttir | |||
| Ayse Ozatilgan | |||
| Christine Geffriaud-Ricouard | |||
| P2860 | cites work | Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database | Q91580618 |
| Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review | Q91665125 | ||
| Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials | Q91981178 | ||
| Olaparib for Metastatic Castration-Resistant Prostate Cancer | Q94446257 | ||
| Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 | ||
| Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science | Q26772883 | ||
| Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). | Q34177200 | ||
| Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 | ||
| Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. | Q38706310 | ||
| Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases | Q38950684 | ||
| Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies | Q38994189 | ||
| Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomi | Q41049323 | ||
| Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy | Q44830519 | ||
| Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post-hoc analysis of COU-AA-301 and COU-AA-302. | Q47316582 | ||
| Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial | Q48161067 | ||
| Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer | Q57109226 | ||
| Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology | Q57113541 | ||
| Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data | Q59795214 | ||
| Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. | Q64916266 | ||
| Progressive osteoporosis during androgen deprivation therapy for prostate cancer | Q73288056 | ||
| Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer | Q81684655 | ||
| Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 | Q89451615 | ||
| International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium | Q89481578 | ||
| Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | Q90366899 | ||
| Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community | Q91367549 | ||
| Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial | Q91436341 | ||
| P577 | publication date | 2020-09-11 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study |
Search more.